RxDoctor Payments DataLook up a doctor →

Mark Scheperle, MD

Internal Medicine · Saint Louis, MONPI 1265417034

Payments from drug & device makers

$89,099in general payments, 2019–2025

Across 1,379 payments — averaging $64.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$43K
  • Otsuka America Pharmaceutical, Inc.$17K
  • Napo Pharmaceuticals Inc$10K
  • Viiv Healthcare Company$3K
  • AbbVie$2K
  • Merck$1K
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$5,2306%
  • Speaking & faculty fees$54,59661%
  • Travel & lodging$5,6856%
  • Food & beverage$23,19726%
  • Education$3750%
  • Entertainment$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead202$43,490
Otsuka America Pharmaceutical, Inc.36$17,161
Napo Pharmaceuticals Inc54$10,082
Viiv Healthcare Company152$2,793
AbbVie(2 entities)175$1,909
Merck60$1,288
Novo Nordisk69$1,211
Pfizer86$1,098
Johnson & Johnson(2 entities)84$939
AstraZeneca(2 entities)52$929
Lilly USA, LLC42$909
Theratechnologies Inc.22$523
EMD Serono, Inc.23$461
Amarin Pharma, Inc.18$381
Takeda Pharmaceuticals U.S.A., Inc.24$377
Amgen(2 entities)23$373
Novartis17$323
Abbott13$278
Antares Pharma, Inc.14$255
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$234
Janssen Products, LP2$199
Astellas Pharma US Inc7$192
Kowa Pharmaceuticals America, Inc.12$187
Medicure Pharma Inc.1$171
GSK12$166
Janssen Scientific Affairs, LLC7$152
Sanofi-aventis U.S. LLC7$126
Aytu Biopharma, Inc.6$113
Sunovion Pharmaceuticals Inc.6$108
Bausch Health US, LLC5$105
Collegium Pharmaceutical, Inc.6$102
Axsome Therapeutics, Inc.4$98
Xeris Pharmaceuticals, Inc.5$98
Biohaven Pharmaceuticals, Inc.5$96
Medtronic(2 entities)4$86
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$85
Corcept Therapeutics3$84
Daiichi Sankyo Inc.5$84
Tris Pharma Inc4$80
Endo Pharmaceuticals Inc.5$79
Exact Sciences3$66
Biohaven Pharmaceutical Holding Company Ltd.3$63
Optinose US, Inc.3$62
Halozyme Inc3$61
Azurity Pharmaceuticals, Inc.4$60
Acerus Pharmaceuticals Corporation3$58
Bayer3$57
Supernus Pharmaceuticals, Inc.3$56
Scilex Pharmaceuticals Inc.3$55
Lundbeck LLC2$55
Teva Pharmaceuticals USA, Inc.3$52
Verity Pharmaceuticals Inc.2$52
Boehringer Ingelheim3$48
Hologic Sales And Service, LLC2$47
Clarus Therapeutics Inc.2$45
Phathom Pharmaceuticals, Inc.2$45
Mylan Institutional Inc.2$44
Acella Pharmaceuticals, LLC2$41
Jazz Pharmaceuticals Inc.2$41
Arbor Pharmaceuticals, Inc.3$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,099 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$80,593
Medicare patients
250
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala217$906,306
SerostimSomatropin41$780,863
DovatoDolutegravir Sodium/Lamivudine74$235,970
GenvoyaElviteg/Cob/Emtri/Tenof Alafen45$209,474
TivicayDolutegravir Sodium68$151,247
DescovyEmtricitabine/Tenofov Alafenam55$142,697
PifeltroDoravirine70$127,354
OdefseyEmtricitab/Rilpiviri/Tenof Ala33$123,181
JulucaDolutegravir/Rilpivirine33$118,137
PrezcobixDarunavir/Cobicistat41$107,033
OzempicSemaglutide74$104,080
OxycontinOxycodone Hcl53$94,461
TriumeqAbacavir/Dolutegravir/Lamivudi22$81,715
MytesiCrofelemer20$71,335
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$69,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$43,490$1,258,477317 claims
EMD Serono, Inc.Serostim$461$780,86341 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq$2,793$587,069197 claims
Johnson & JohnsonPrezcobix, Complera, Xarelto$939$171,54881 claims
MerckPifeltro$1,288$127,35470 claims
Novo NordiskOzempic$1,211$104,08074 claims
Lilly USA, LLCMounjaro, Trulicity$909$71,63942 claims
Napo Pharmaceuticals IncMytesi$10,082$71,33520 claims
Janssen Products, LPSymtuza$199$69,20215 claims
PfizerEliquis$1,098$48,11646 claims
GSKTrelegy Ellipta, Breo Ellipta$166$32,91846 claims
AstraZenecaFarxiga, Breztri Aerosphere$929$20,80123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →